With first hu­man da­ta, long-strug­gling Si­lence Ther­a­peu­tics leaps in­to next big car­dio­vas­cu­lar race

Drug com­pa­nies have spent the last 40-plus years search­ing for in­creas­ing­ly high-tech ways of low­er­ing bad cho­les­terol in hopes of curb­ing heart dis­ease, still the lead­ing cause of death world­wide.

There are po­ten­tial­ly oth­er ways of curb­ing heart dis­ease for mil­lions, how­ev­er. For ex­am­ple, a fat-trans­port mol­e­cule called lipopro­tein a, or lp(a), ap­pears to in­crease heart dis­ease risk for 20% to 30% of the world pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER